And on that list of stocks that managed to buck the trend is IndiGrid Infrastructure Investment Trust (IG InvIT), managing to deliver 2.7 per cent (capital appreciation along with distribution ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...

Interested individuals and institutional investors can now participate in the landmark Sharia-compliant IPO until 30th January, 2025. The fund was established through a partnership between the ...

Representative image MUMBAI: NDR InvIT Trust on Tuesday announced it has acquired a Grade-A industrial and warehousing portfolio for Rs 706.1 crore. Spread across Surat, Hyderabad, Bengaluru, and Pune ...

(Bloomberg) -- Booming credit markets are throwing private equity firms a lifeline as they strive to return cash to investors: Instead of relying on the IPO market ... debt to fund a $4.5 billion ...

MANILA, Philippines — E-wallet giant GCash will spend the proceeds from its initial public offering (IPO) on expanding the lending business and speeding up international growth, its top ...

(Bloomberg) — Asyad Group SAOC, backed by Oman’s sovereign wealth fund, unveiled plans for the initial public ... Those two large deals propelled Oman ahead of the UK in terms of IPO fundraising ...

Company cuts upper valuation guidance to $65 bln from $110 bln Investors balked at long-term sales guidance in IPO prospectus IPO a rare opportunity to buy equity in U.S. LNG exporter Also seen as ...

An earlier version of this story misspelled the name of Smithfield Foods Inc. in its headline. Smithfield Foods Inc. is offering Wall Street a seat at the table for potential growth in its ...

Private Equity Has a Plan If IPOs Don’t Work: Add Debt ‘Triple track’ options open to PE for portfolio companies Dividend recaps enabled by strong credit market, CLO revival ...

[an IPO is] the plan.” Mistral, which Mensch launched in 2023 alongside former researchers from Google’s DeepMind and Meta, is often described as Europe’s answer to U.S. incumbents like OpenAI.

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an early look at how receptive public investors could be to biotech listings ...